Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Akers Biosciences sets up Kenya deal, predicts profit

This article was originally published in Clinica

Executive Summary

In common with many of its healthcare counterparts, point of care diagnostics producer Akers Biosciences has seen its share price under pressure this year. Since its AIM launch in London in May 2002 (see Clinica No 1008, p 14), the US company's price has slipped from an opening 135p ($2.10) to 53p. CEO Ray Akers, on a visit to London last week, told Clinica: "We're not alone in experiencing declining share prices."





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts